Related Experiment Video
Updated: Sep 25, 2025

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis
Published on: November 10, 2023
Acute Promyelocytic Leukemia in a Patient With Chronic Continuous Type of Crohn's Disease
Shiori Kinoshita1, Satoshi Tanida2, Akimi Kawai3
1Department of Hematology, Toyokawa City Hospital, Toyokawa City, Aichi Prefecture, Japan.
Insights
Chronic inflammation from Crohn's disease may cause mutations in hematopoietic stem cells (HSCs), potentially leading to acute promyelocytic leukemia (APL). This rare APL manifestation highlights the need for vigilance in Crohn's disease patients.
Area of Science:
- Hematology
- Oncology
- Gastroenterology
Background:
- Chronic inflammation is a known risk factor for leukemogenesis.
- Crohn's disease is a chronic inflammatory condition affecting the gastrointestinal tract.
Observation:
- A patient with long-standing Crohn's disease developed acute promyelocytic leukemia (APL).
- The patient was diagnosed with Crohn's disease at age 28 and APL at age 51, having received biologic therapy but not azathioprine.
Findings:
- The development of APL in this case suggests a potential link between chronic inflammation from Crohn's disease and leukemic transformation.
- Genomic instability in hematopoietic stem cells (HSCs) due to chronic inflammation may predispose individuals to APL.
Implications:
- This case underscores the importance of monitoring Crohn's disease patients for rare hematological malignancies like APL.
- Further research is warranted to elucidate the mechanisms linking chronic inflammation in Crohn's disease to HSC genomic instability and leukemogenesis.
Abstract:
Chronic inflammation can induce leukemogenic mutations in hematopoietic stem cells (HSCs). We report a case of acute promyelocytic leukemia (APL) in a patient with chronic continuous type of Crohn's disease. The patient had been diagnosed with Crohn's disease at the age of 28 years and had received conventional treatments with biologics, but not azathioprine. At the age of 51, he was diagnosed with APL with ider(17). Long-term exposure to chronic continuous inflammation from Crohn's disease might be a factor inducing genomic instability in HSCs, which lead to the subsequent development of APL. APL is a rare hematological manifestation that required attention in Crohn's disease patients.
More Related Videos
07:38Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Differentiation of Common Myeloid Progenitor Cells